Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$27.54 USD
+0.05 (0.18%)
Updated May 17, 2024 04:00 PM ET
After-Market: $27.53 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IART 27.54 +0.05(0.18%)
Will IART be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Deciphering Integra (IART) International Revenue Trends
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
Other News for IART
IART July 19th Options Begin Trading
Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference
Integra LifeSciences: Expansion, Audits, and Share Repurchase Plan
Integra Lifesciences (IART) Receives a Sell from J.P. Morgan
Target upgraded, CVS downgraded: Wall Street's top analyst calls